Estrogen therapy for castrate resistant prostate cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1020959

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Withdrawal of male hormones in men with prostate cancer is effective therapeutically because it causes cell death in most of the tumour. However the remaining cells (called castrate resistant cells), give rise to recurrent disease that inevitably kills the patient. This project aims to test if our compound will kill these cells and prevent recurrence or if it has any benefit for the patients who have incurable disease.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $531,690.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Solid Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

androgen independent prostate cancer | endocrine tumours | oestrogen receptor | prostate biology | prostate cancer

Related Links